Core Scientific's merger with CoreWeave just picked up two lawsuits and a revised valuation table.

The October 22 8-K is a proxy supplement, not a deal change. The Merger Agreement signed July 7, 2025 stands. CoreWeave's Merger Sub will merge with and into Core Scientific, leaving Core Scientific as a wholly owned subsidiary of CoreWeave. What changed is the disclosure record around that deal.

The Litigation Is Now on the Record

Two purported $CORZ stockholders filed suit in Connecticut Superior Court, Bridgeport Judicial District, in the Barcia case. The 8-K does not characterize the claims as meritorious or disclose a settlement. The filing's purpose is to supplement the proxy statement and prospectus already on file, not to signal deal risk. Merger-related stockholder litigation at this stage is common, and the disclosure here follows standard practice of updating the proxy record before the shareholder vote.

What matters is whether the litigation produces an injunction or a settlement that alters deal terms. The 8-K discloses neither.

Revised Valuation Tables Narrow the Spread

The more substantive content in the filing is the amended financial advisor analysis. Moelis revised its selected publicly traded companies table for Core Scientific. The updated figures show Core Scientific's consensus TEV at $7.696 billion as of July 3, 2025, implying a TEV/Adjusted EBITDA multiple of 19.8x on a current-year basis and 12.5x on a 2027 estimate. The unaffected consensus TEV, measured as of June 25, 2025 before the deal announcement, was $5.005 billion, implying 12.8x current-year and 8.2x on the 2027 estimate.

The peer set Moelis used includes Equinix at a $92.005 billion TEV, Digital Realty at $73.104 billion, Keppel DC REIT at $5.249 billion, and Digital Core REIT at $1.331 billion. The peer group mean TEV/Adjusted EBITDA sits at 19.3x current-year and 17.6x on the 2027 estimate, with a median of 19.4x and 17.5x respectively. Core Scientific's post-announcement consensus multiple sits at the peer mean on a current-year basis but trails significantly on the forward estimate, 12.5x against a peer median of 17.5x.

PJT Partners' DCF analysis applied an exit multiple range of 18.0x to 22.0x to Core Scientific's terminal-year Adjusted EBITDA, which management estimated at $899 million on a forward NTM basis. For CoreWeave, PJT used a 20.0x to 30.0x exit multiple range applied to terminal-year Adjusted EBIT from CoreWeave's standalone projections.

Director Compensation at the Close

The filing quantifies RSU acceleration for $CORZ's five non-employee directors. The aggregate estimated value of unvested RSU awards that would vest at the effective time of the merger is $8.515 million. Four directors, Jeff Booth, Jordan Levy, Yadin Rozov, and Eric Weiss, each hold awards estimated at $1.972 million. Elizabeth Crain's unvested awards are estimated at $623,952. These figures are based on assumptions described in the proxy and are not guaranteed closing values.

Director compensation disclosures of this type are required proxy supplements when the original filing omitted or understated the amounts. The revision itself does not indicate a problem with the deal structure.

Where CORZ Sits Heading Into the Vote

$CORZ's Filing Risk Score sits at 100, anchored on the density of merger-related filings the company has generated since July. The Form S-4 was filed August 20, amended September 17 and September 25, and a definitive proxy landed September 26. This 8-K is the latest layer. The elevated disclosure cadence reflects the merger process, not operational distress.

The BTC Exposure Score is 80, reflecting $CORZ's position as a Bitcoin miner and hosting operator where fleet economics and power contracts remain the underlying business even as the merger process dominates the filing calendar.

On price, $CORZ has gained roughly 17% over the past month and is up more than 59% year to date through May 20, 2026, trading above its 20-day, 50-day, and 200-day moving averages. The stock hit a 52-week high of $25.17 on May 14, 2026. The merger arbitrage spread, not $CORZ's operating fundamentals, is now the dominant price driver.

The registration statement, proxy, and prospectus are the documents to watch. Any amendment to the Merger Agreement, a court order affecting the vote, or a competing bid would change the read materially. The supplemental disclosures filed October 22 do not move any of those variables.

Research only. Not investment advice.